Leqembi Approval Opens Door To Alzheimer’s Market For Lilly And Others
Pointers On Competition Expected From Lilly’s Full Phase III Data
Full approval for Leqembi is not only a breakthrough for Eisai and Biogen, it will also give companies and investors greater confidence in investing in more novel Alzheimer’s therapies.
